View AMCP comments to the FDA on considerations in demonstrating biosimilar interchangeability with a biologic reference product.
AMCP submitted a letter on the reopened comment period for the Medicaid Coverage of Innovative Technologies rule, which created a pathway for fast national Medicare coverage of innovative technologies, including digital therapeutics.
AMCP webinar that discussed the health care policy landscape under the 117th Congress and Biden Administration.
AMCP webinar that discussed the health care policy landscape under the 117th Congress and Biden Administration.
AMCP webinar that discussed the health care policy landscape under the 117th Congress and Biden Administration.
On January 25, 2019, AMCP provided comments to CMS in response to its proposed rule on lowering drug prices and reducing out-of-pocket expenses in the Medicare program. The letter outlines the proposal’s impact on providing plan flexibility to manage protected classes, prohibition against gag clauses in pharmacy contracts, E-Prescribing and the Part D Prescription Drug Program, Part D explanation of benefits, and Medicare Advantage and step therapy in Part B.
On February 26, 2018, AMCP joined 11 organizations in letter to the OIG in support of establishing a safe harbor provision that would encourage the development of additional value-based contracts for the Medicare and Medicaid populations.
